With biggest weight loss da­ta in hand, Eli Lil­ly races to start trio of PhI­II tri­als for its ‘triple-G’ can­di­date next month

Eli Lil­ly is revving the en­gines for the next stage of the weight loss drug rev­o­lu­tion with a trio of large Phase III stud­ies set to be­gin Aug. 7, per re­cent up­dates to the fed­er­al clin­i­cal tri­als data­base.

The stud­ies will in­ves­ti­gate whether Lil­ly’s so-called “triple-G” drug re­ta­tru­tide can repli­cate the eye-pop­ping re­sults re­port­ed last month from a mid-stage tri­al, show­ing about 24% weight re­duc­tion among a sub­set of pa­tients in a 338-per­son tri­al af­ter near­ly a year of treat­ment. That’s the most dra­mat­ic weight loss da­ta the in­dus­try has seen out of a class of drugs that aims to curb ap­petite.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER